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Low-Dose Aspirin for Primary Prevention of Cardiovascular Disease:
Use Patterns and Impact Across Race and Ethnicity in the Southern
Community Cohort Study
Rodrigo Fernandez-Jimenez, MD, PhD; Thomas J. Wang, MD; Valentin Fuster, MD, PhD; William J. Blot, PhD
Background-—Data are limited on use patterns of low-dose aspirin and its role for primary prevention of cardiovascular disease
(CVD) in different racial and ethnic groups.
Methods and Results-—Overall, 65 231 non-Hispanic black and white people aged 40 to 79 years with no history of CVD enrolled
from 2002 through 2009 in the SCCS (Southern Community Cohort Study). At cohort entry, the simplified Framingham 10-year
CVD risk was calculated, and data related to low-dose aspirin use and clinical and socioeconomic covariates were collected. Race-
and ethnicity-specific adjusted odds ratios for characteristics of low-dose aspirin users and hazard ratios for ischemic cardiac
death according to aspirin use were calculated using multivariate logistic and Cox regression models. Black participants were less
likely to take low-dose aspirin compared with white participants, regardless of CVD risk and covariates (adjusted odds ratio: 0.79;
95% CI, 0.75–0.82). Over a median follow-up of 11.3 years, low-dose aspirin use was associated with a trend toward decreased
risk of ischemic cardiac death in white participants (adjusted hazard ratio: 0.86; 95% CI, 0.68–1.10), especially in women (adjusted
hazard ratio: 0.72; 95% CI, 0.51–1.02), but not in black participants (adjusted hazard ratio: 1.18; 95% CI, 0.98–1.40). Similar trends
were observed when the analysis was restricted to high-risk individuals aged 50 to 69 or 50 to 59 years, ages for which guidelines
consider aspirin for CVD primary prevention.
Conclusions-—Low-dose aspirin use for primary prevention of CVD is lower among black than white patients. Its use might be
associated with a disparate impact on ischemic cardiac death according to race and ethnicity. Although additional studies are
required, these findings provide no evidence of a beneficial effect of aspirin among black patients for CVD primary prevention.
( J Am Heart Assoc. 2019;8:e013404. DOI: 10.1161/JAHA.119.013404.)
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I n 2016, the US Preventive Services Task Force (USPSTF)recommended that physicians consider initiating low-dose
aspirin for the primary prevention of cardiovascular disease
(CVD) in adults aged 50 to 59 years with a high predicted risk
of CVD and without elevated bleeding risk.1 The decision to
initiate low-dose aspirin in high-risk adults aged 60 to
69 years should be an individual one, according to the
USPSTF.1 Nevertheless, researchers recognized a significant
evidence gap regarding recommendations for CVD primary
prevention in subpopulations.2
Current evidence is insufficient to assess the balance of
benefits and harms of initiating aspirin for the primary
prevention of CVD in adults aged <50 or ≥70 years. Notably,
no data exist on the role of aspirin therapy in different racial
and ethnic groups.1 The benefit of aspirin for primary
prevention has not been assessed in black Americans because
major trials did not include a sufficient sample to perform
subgroup analyses by race/ethnicity.3,4 Similarly, little infor-
mation is available on the patterns of low-dose aspirin use for
primary prevention of CVD by race/ethnicity.5–8
The objectives of this study were to analyze the prevalence
and patterns of low-dose aspirin use for the primary
prevention of CVD and to study the association between
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low-dose aspirin use and CVD incidence by race/ethnicity in
the SCCS (Southern Community Cohort Study). The SCCS is
an ongoing, large, prospective, cohort study designed to
investigate the incidence of various chronic diseases, includ-
ing differential patterns by race/ethnicity and sex in a low-
income underinsured US population that is underrepresented
in previous studies.9
Methods
Study Sample and Data Collection
Between 2002 and 2009, the SCCS enrolled 85 000 adults
(approximately two thirds black Americans) who were aged 40
to 79 years and residing in 12 states in the southeastern
United States. A detailed description of SCCS methods was
published previously.9 Briefly, sociodemographic data, life-
style and anthropometric characteristics, and personal med-
ical history were ascertained at cohort enrollment through
standardized computer-assisted personal interviews for com-
munity health center participants (86% of participants) and a
self-administered mailed questionnaire for the general popu-
lation participants (14% of participants).
For this study, we used data obtained from the SCCS
Baseline Questionnaire (available at https://www.southernc
ommunitystudy.org/). Participants who reported having a
prior myocardial infarction, coronary artery bypass surgery,
stroke, and/or transient ischemic attack were excluded.
Analyses were restricted to self-reported black or non-
Hispanic black and non-Hispanic white SCCS participants
because too few participants in other racial/ethnic groups
were available for stable statistical analysis.10,11 SCCS
participants provided written informed consent, and protocols
were approved by the institutional review boards of Vanderbilt
University Medical Center and Meharry Medical College. A
data access request was submitted via the SCCS Online
Request System, and the research proposal was approved
under the request identifier 219. Data and methods used in
the analysis are available from the corresponding author on
reasonable request and approval by the SCCS Data and
Biospecimen Use Committee.
Definition of Low-Dose Aspirin Use and Other
Variables of Interest
Information regarding low-dose aspirin use was obtained at
enrollment. Participants were asked if they used low-dose aspirin
regularly in the previous year to prevent heart disease or stroke.
Low-dose aspirin was defined as baby aspirin, half tablets of
aspirin, or low-dose aspirin itself. Regular use was defined as
taking low-dose aspirin ≥2 days/week for ≥1 month. Self-
reported medical history of peptic ulcer or concomitant use of
over-the-counter NSAIDs was also collected.
Year of SCCS enrollment was classified in the following
categories: 2002–2003, 2004–2005, 2006–2007, and 2008–
2009. Participant age at enrollment (baseline interview) was
classified in the following categories: 40 to 49, 50 to 59, 60 to
69, and 70 to 79 years. Annual household income was
reported in categories of <$15 000, $15 000 to $24 999,
$25 000 to $49 999, $50 000 to $99 999, and $100 000 or
more, with the 2 highest categories combined owing to small
numbers. Educational attainment was classified as less than
high school (<12 years), high school completed (12 years;
completed high school or General Educational Development),
or higher than high school (some education beyond completion
of high school including vocational school, some college or
junior college, and college graduate or beyond). Health
insurance coverage was classified as none or coverage by
any type of health insurance including Medicaid, Medicare,
private or employer insurance, military insurance, and “other”
types of insurance.
Calculation of Predicted CVD Risk
The 10-year CVD risk for each participant at enrollment was
calculated by using the simplified Framingham risk equation,
which includes age, diabetes mellitus, smoking, treated and
untreated systolic blood pressure (SBP), and body mass index
(as replacement for lipid levels), and standardized assignment
of points for each component.12 As described previously,
10-year CVD risk was stratified into 3 mutually exclusive
Clinical Perspective
What Is New?
• This study, which included 65 231 adults without known
cardiovascular disease who were from the southeastern
United States and followed up for 11 years, is one of the
first to determine the prevalence of low-dose aspirin use for
primary prevention and its association with incident fatal
ischemic heart disease in a predominantly high-risk, low-
income, non-Hispanic black and non-Hispanic white popu-
lation.
• Low-dose aspirin use for primary prevention of cardiovas-
cular disease was consistently lower among black than
white participants, and its use might be associated with a
disparate impact on ischemic cardiac death according to
race and ethnicity.
What Are the Clinical Implications?
• Although additional studies are required, our findings
provide no evidence of a beneficial effect of aspirin use
among black patients for cardiovascular disease primary
prevention.
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categories: low risk (<6%), intermediate risk (6–9.9%), and high
risk (≥10%).6,13 Actual information for calculating the SBP
component of the score was available only for a proportion of
SCCS participants assessed at community health centers
(n=9568, 15%). Missing SBP values were imputed using the
normal values as presented in the 2008 generalized CVD
calculator study and as done previously by others.12,14
Consequently, values of 125 and 135 mm Hg of SBP were
assigned respectively for those participants without or with a
diagnosis of hypertension (defined as high blood pressure
reported by a doctor at any time). A sensitivity analysis was
performed in the subset of participants with SBP measure-
ments by comparing the assigned overall risk category
accounted with actual measured versus imputed blood
pressure values. The global agreement and area under the
receiver operating characteristic curve between both esti-
mated risks were 87.0% (95% CI, 86.3–87.7%) and 0.86 (95%
CI, 0.85–0.87), respectively.
Outcome Follow-Up
Vital status and cause of death were ascertained by linkage of
the cohort with the US Social Security Administration’s Death
Master File and the National Death Index, respectively. Death
due to ischemic heart disease was defined as International
Classification of Diseases, Tenth Revision (ICD-10) codes
I20–I25. Follow-up of vital status was extended through
December 31, 2016. The follow-up duration was defined as
the number of months between a participant’s date of
enrollment and date of death, date lost to follow-up, or
December 31, 2016, whichever occurred first.
Statistical Analysis
We computed means and standard deviations or median and
interquartile range for continuous variables and counts and
percentages for categorical variables. Chi-square tests were
used to test for unadjusted differences in prevalences of low-
dose aspirin use across categories of participant character-
istics within low-, intermediate-, and high-risk CVD groups.
Multivariate logistic regression models were used for the
adjusted analysis of factors associated with low-dose aspirin
use for CVD primary prevention. Covariates were selected a
priori based on previous literature5,6 or on their potential
influence on drug prescription (eg, history of ulcer, concomi-
tant use of NSAIDs).2,15 Insurance coverage was not included
in the models because of known collinearity issues with
household income and education.6 Results were reported as
odds ratios with 95% CIs. The full adjusted model was
subsequently stratified for the study of the prevalence of low-
dose aspirin use in high-risk participants by race/ethnicity
across different categories of covariates of interest.
Ischemic cardiac death incidence rates were calculated by
dividing the number of event cases by person-time of follow-
up and were presented per 1000 person-years stratified by
age, sex, and race/ethnicity. The 95% CIs were calculated
using the quadratic approximation to the Poisson log likeli-
hood for the log-rate parameter.16
For the analysis of the association of low-dose aspirin use
and ischemic cardiac death, the failure distributions during
follow-up of participants with and without low-dose aspirin
treatment were estimated by the Kaplan–Meier method,
followed by the Cox proportional hazards regression model.
Covariates were selected a priori based on their described
association with ischemic heart disease (clinical plausibility)
or a potential confounding effect, including 10-year CVD risk
category, age of the participant at enrollment, sex, race/
ethnicity, diabetes mellitus status, and annual household
income. Subpopulation analyses were performed in high-risk
participants according to the USPSTF 2016 guidelines on low-
dose aspirin use for primary prevention of CVD (grade B
recommendation for the 50–59 age group; grade C recom-
mendation for the 60–69 age group). The proportional
hazards assumption was confirmed by including time-
dependent covariates and by performing the Schoenfeld
residual-based test of proportional hazards. As a sensitivity
analysis, competing-risk regression models that account for
other mortality causes were run and showed similar results
(data not shown).
As an additional sensitivity analysis, multiple imputation
using chained equations as implemented by the command mi
was performed to impute the SBP component of the
Framingham risk score. Missing SBP values were filled using
a truncated regression imputation method with a restricted
range. The range used was the one observed in the
participants with actual SBP values (ie, lower limit:
78 mm Hg; upper limit: 244 mm Hg). The following variables
were included as auxiliary variables: age, sex, race/ethnicity,
body mass index, diabetes mellitus status, hypertension
status, antihypertensive medication use, and insurance cov-
erage. Number of imputations was set at 50. A random-
number seed was set to ensure reproducibility of the imputed
values. Estimations on the imputed data were run with the mi
estimate command using similar multivariate logistic regres-
sion and Cox proportional hazards regression models, as
described earlier. The estimations adjust coefficients and
standard errors for the variability between imputations
according to the combination rules by Rubin.17 Estimation
to continue was allowed even if the estimation sample varied
across imputations. Diagnostic checks of the imputation
model were obtained using the vartable and dftable options of
the mi estimate command.
All statistical analyses were performed using Stata v15.1
(StataCorp).
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Results
General Characteristics of the Population
The flow chart of the study is shown in Figure 1. A total
of 65 231 SCCS participants without prior CVD were
included in this analysis. Average age at enrollment was
51.5 years (SD: 8.5). The participants were 60.1% female,
70.2% non-Hispanic black, and 29.8% non-Hispanic white.
Approximately two thirds of the population showed high
predicted 10-year CVD risk at enrollment, whereas 20%
and 13% showed intermediate and low risk, respectively. A
detailed description of the sociodemographic and clinical
characteristics of the population at enrollment, stratified by
10-year CVD risk categories, is presented in Table 1.
Figure 1. Study flow chart. A total of 65 231 SCCS (Southern Community Cohort Study) participants
were included in this study. *Information of interest included vital status and the following variables
obtained from the SCCS baseline questionnaire: year of SCCS enrollment, age at enrollment, sex,
hypertension status, smoking status, diabetes mellitus status, body mass index, low-dose aspirin use, race/
ethnicity, household income, education, concomitant use of NSAIDs, and medical history of ulcer. CABG
indicates coronary artery bypass grafting; CVD, cardiovascular disease; MI, myocardial infarction; TIA,
transient ischemic attack.
DOI: 10.1161/JAHA.119.013404 Journal of the American Heart Association 4
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Prevalence of Low-Dose Aspirin Use and Impact
Across Race and Ethnicity
The average crude prevalence of low-dose aspirin use for the
primary prevention of CVD in the overall SCCS population was
17.1% and increased across predicted 10-year CVD risk
categories: 7.5%, 11.6%, and 20.4% among low-, intermediate-,
and high-risk participants, respectively (P<0.001). Among low-
dose aspirin users, the median number of pills consumed was
7 pills/week (first quartile: 7; third quartile: 7). A detailed
description of the prevalence of low-dose aspirin use by 10-year
CVD risk categories according to different sociodemographic
and clinical characteristics is presented in Table 2. The preva-
lence of low-dose aspirin use initially increased in the partici-
pants enrolled from 2002–2003 to 2006–2007 and then
stabilized thereafter. Higher prevalence of low-dose aspirin
use was observed among participants who were older, female,
white, diabetic, and users of NSAIDs; who reported having some
Table 1. Clinical and Sociodemographic Characteristics of the SCCS Population by 10-Year CVD Risk Categories
Variable Low Risk (n=8231) Intermediate Risk (n=12 409) High Risk (n=44 591) P Value*
Year of SCCS enrollment <0.001
2002–2003 2215 (26.9) 3342 (26.9) 12 905 (28.9)
2004–2005 3320 (40.3) 4969 (40.0) 16 189 (36.3)
2006–2007 1768 (21.5) 2700 (21.8) 9647 (21.6)
2008–2009 928 (11.3) 1398 (11.3) 5850 (13.1)
Age, y <0.001
40–49 7108 (86.4) 8463 (68.2) 15 710 (35.2)
50–59 1096 (13.3) 3352 (27.0) 17 808 (39.9)
60–69 27 (0.3) 587 (4.7) 8476 (19.0)
70–79 0 (0.0) 7 (0.1) 2597 (5.8)
Sex <0.001
Female 7798 (94.7) 10 181 (82.1) 21 219 (47.6)
Male 433 (5.3) 2228 (18.0) 23 372 (52.4)
Race/ethnicity <0.001
Black 5566 (67.6) 8384 (67.6) 31 822 (71.4)
White 2665 (32.4) 4025 (32.4) 12 769 (28.6)
Diabetes mellitus <0.001
No 8202 (99.7) 12 035 (97.0) 32 581 (73.1)
Yes 29 (0.4) 374 (3.0) 12 010 (26.9)
Health insurance <0.001
No 3389 (41.3) 5503 (44.5) 18 345 (41.3)
Yes 4818 (58.7) 6867 (55.5) 26 095 (58.7)
Annual household income <0.001
<$15 000 3793 (46.1) 6247 (50.3) 25 913 (58.1)
$15 000 to <$25 000 1898 (23.1) 2804 (22.6) 9497 (21.3)
$25 000 to <$50 000 1401 (17.0) 1984 (16.0) 5741 (12.9)
≥$50 000 1139 (13.8) 1374 (11.1) 3440 (7.7)
Education <0.001
Less than high school 1568 (19.1) 2747 (22.1) 14 190 (31.8)
High school completed 2714 (33.0) 4324 (34.9) 15 135 (33.9)
Higher than high school 3949 (48.0) 5338 (43.0) 15 266 (34.2)
Values are frequencies (percentages). Framingham 10-year CVD risk scores were stratified into 3 mutually exclusive categories: low risk (<6%), intermediate risk (6–9.9%), and high risk
(≥10%). CVD indicates cardiovascular disease; SCCS, Southern Community Cohort Study.
*Crude frequency distributions of categorical variables among categories of CVD risk scores were compared using chi-square tests.
DOI: 10.1161/JAHA.119.013404 Journal of the American Heart Association 5


















 http://ahajournals.org by on O
ctober 20, 2020
Table 2. Prevalence of Low-Dose Aspirin Use for Primary Prevention of CVD by 10-Year CVD Risk Categories, According to
Different Sociodemographic and Clinical Characteristics, in the SCCS
Variable
Prevalence of Low-Dose Aspirin Use, n (%)
Low Risk (n=8231) P Value* Intermediate Risk (n=12 409) P Value* High Risk (n=44 591) P Value*
Year of SCCS enrollment <0.001 <0.001 <0.001
2002–2003 101 (4.6) 244 (7.3) 1784 (13.8)
2004–2005 285 (8.6) 638 (12.8) 3524 (21.8)
2006–2007 161 (9.1) 368 (13.6) 2421 (25.1)
2008–2009 67 (7.2) 192 (13.7) 1358 (23.2)
Age, y <0.001 <0.001 <0.001
40–49 451 (6.3) 746 (8.8) 1820 (11.6)
50–59 156 (14.2) 540 (16.1) 3718 (20.9)
60–69 7 (25.9) 155 (26.4) 2611 (30.8)
70–79  1 (14.3) 938 (36.1)
Sex 0.001 <0.001 <0.001
Female 600 (7.7) 1296 (12.7) 5464 (25.8)
Male 14 (3.2) 146 (6.6) 3623 (15.5)
Race/ethnicity <0.001 <0.001 <0.001
Black 341 (6.1) 818 (9.8) 5665 (17.8)
White 273 (10.2) 624 (15.5) 3422 (26.8)
Diabetes mellitus 0.908 <0.001 <0.001
No 612 (7.5) 1375 (11.4) 5238 (16.1)
Yes 2 (6.9) 67 (17.9) 3849 (32.1)
History of ulcer 0.004 0.364 0.002
No 537 (7.2) 1281 (11.5) 7882 (20.2)
Yes 77 (10.1) 161 (12.4) 1205 (22.0)
Concomitant NSAIDs <0.001 <0.001 <0.001
No 433 (6.6) 984 (10.1) 6851 (18.9)
Yes 181 (10.9) 458 (17.4) 2236 (27.0)
Health insurance 0.032 <0.001 <0.001
No 228 (6.7) 516 (9.4) 2785 (15.2)
Yes 385 (8.0) 918 (13.4) 6267 (24.0)
Annual household income <0.001 <0.001 <0.001
<$15 000 229 (6.0) 570 (9.1) 4549 (17.6)
$15 000 to <$25 000 116 (6.1) 322 (11.5) 1938 (20.4)
$25 000 to <$50 000 133 (9.5) 279 (14.1) 1456 (25.4)
≥$50 000 136 (11.9) 271 (19.7) 1144 (33.3)
Education <0.001 <0.001 <0.001
Less than high school 90 (5.7) 232 (8.5) 2526 (17.8)
High school completed 180 (6.6) 450 (10.4) 2846 (18.8)
Higher than high school 344 (8.7) 760 (14.2) 3715 (24.3)
Values are frequencies (percentages). Framingham risk scores were stratified into 3 mutually exclusive categories: low risk (<6%), intermediate risk (6–9.9%), and high risk (≥10%). CVD
indicates cardiovascular disease; SCCS, Southern Community Cohort Study.
*Crude frequency distributions of categorical variables within each category of CVD risk were compared using chi-square tests.
DOI: 10.1161/JAHA.119.013404 Journal of the American Heart Association 6
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Table 3. Multivariate Analysis of Factors Associated With Low-Dose Aspirin Use for Primary Prevention of CVD in the SCCS
Variable
Model 1 Model 2 Model 3
OR (95% CI) P Value* OR (95% CI) P Value* OR (95% CI) P Value*
Race/ethnicity
White Ref. Ref. Ref.
Black 0.61 (0.59–0.64) <0.001 0.73 (0.70–0.76) <0.001 0.79 (0.75–0.82) <0.001
Year of SCCS enrollment
2002–2003 . . . . . . Ref. Ref.
2004–2005 . . . . . . 1.57 (1.48–1.66) <0.001 1.41 (1.33–1.50) <0.001
2006–2007 . . . . . . 1.87 (1.75–1.99) <0.001 1.77 (1.66–1.89) <0.001
2008–2009 . . . . . . 1.65 (1.54–1.78) <0.001 1.61 (1.49–1.74) <0.001
Age, y
40–49 . . . . . . Ref. Ref.
50–59 . . . . . . 1.79 (1.70–1.89) <0.001 1.77 (1.67–1.87) <0.001
60–69 . . . . . . 2.82 (2.64–3.00) <0.001 2.87 (2.69–3.06) <0.001
70–79 . . . . . . 3.52 (3.21–3.87) <0.001 3.97 (3.60–4.37) <0.001
Sex
Female . . . . . . Ref. Ref.
Male . . . . . . 0.65 (0.62–0.68) <0.001 0.74 (0.70–0.77) <0.001
10-y CVD risk
Low risk . . . . . . Ref. Ref.
Intermediate risk . . . . . . 1.46 (1.32–1.62) <0.001 1.46 (1.31–1.61) <0.001
High risk . . . . . . 2.49 (2.27–2.73) <0.001 1.96 (1.78–2.16) <0.001
Diabetes mellitus
No . . . . . . . . . . . . Ref.
Yes . . . . . . . . . . . . 2.45 (2.33–2.58) <0.001
History of ulcer
No . . . . . . . . . . . . Ref.
Yes . . . . . . . . . . . . 1.06 (1.00–1.14) 0.060
Concomitant NSAIDs
No . . . . . . . . . . . . Ref.
Yes . . . . . . . . . . . . 1.53 (1.45–1.61) <0.001
Annual household income
<$15 000 . . . . . . . . . . . . Ref.
$15 000 to <$25 000 . . . . . . . . . . . . 1.18 (1.11–1.25) <0.001
$25 000 to <$50 000 . . . . . . . . . . . . 1.41 (1.32–1.51) <0.001
≥$50 000 . . . . . . . . . . . . 1.85 (1.72–2.00) <0.001
Education
Less than high school . . . . . . . . . . . . Ref.
High school completed . . . . . . . . . . . . 1.13 (1.07–1.20) <0.001
Higher than high school . . . . . . . . . . . . 1.25 (1.18–1.33) <0.001
Model 1 includes race/ethnicity. Model 2 includes model 1 plus year of SCCS enrollment, age at enrollment, sex, and Framingham 10-year CVD risk category. Model 3 includes model 2
plus diabetes mellitus status, history of ulcer, concomitant use of NSAIDs, annual household income, and education level. CVD indicates cardiovascular disease; OR, odds ratio; Ref.,
referent; SCCS, Southern Community Cohort Study.
*P value from Wald test compared with ref.
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type of health insurance coverage; and who had higher
household income or education level. Most of these findings
were consistent across all CVD risk categories. In contrast, no
consistent differences in the use of low-dose aspirin were shown
in relation to medical history of peptic ulcer.
These results were confirmed in the multivariate analysis of
factors associated with low-dose aspirin use (Table 3). In the
full adjusted model, non-Hispanic black participants were less
likely to use low-dose aspirin for the primary prevention of
CVD compared with white participants (low-dose aspirin use,
adjusted odds ratio: 0.79; 95% CI, 0.75–0.82; P<0.001).
Similar results were observed when the analysis was
restricted to the high-risk CVD group (low-dose aspirin use,
adjusted odds ratio; 0.77; 95% CI, 0.73–0.82; P<0.001). Such
racial/ethnic differences among high-risk individuals were
more prominent among those who were recruited before
2006, younger than 60 years of age, male, and nondiabetic;
who did not report concomitant use of NSAIDs; and who
reported lower household income or lower education level
(Figure 2). Similar results were observed on multiple imputed
data sets (Table 4).
Association Between Low-Dose Aspirin Use and
Fatal Ischemic Heart Disease
After a median follow-up of 135 months (interquartile range:
110–154 months), there were 11 489 deaths including 1225
deaths due to ischemic heart disease. The overall incidence
rate of ischemic cardiac death in the SCCS population was
1.76 per 1000 person-years (95% CI, 1.66–1.86) and was
20% higher in white than black participants (incidence rate
ratio: 1.21; 95% CI, 1.07–1.36). The incidence rate of
ischemic cardiac death was consistently higher in white than
black participants across most age and sex categories
(Table 5).
In the overall population, low-dose aspirin use was
associated with a trend toward decreased risk of ischemic
cardiac death in white participants (adjusted hazard ratio:
0.86; 95% CI, 0.68–1.10), especially in women (adjusted
hazard ratio: 0.72; 95% CI, 0.51–1.02), but not in black
participants (adjusted hazard ratio: 1.18; 95% CI, 0.98–1.40).
Similar results were observed when the analysis was
restricted to the high CVD risk group as a whole (Table 6)
and to high-risk individuals aged 50 to 69 or 50 to 59 years
(Figure 3). Similar results were observed in multiple imputed
data sets (Table 7).
Discussion
This population-based study examines the prevalence of low-
dose aspirin use and its association with incident fatal
ischemic heart disease in a large cohort of non-Hispanic black
and non-Hispanic white adults without known CVD who were
recruited in 2002 through 2009 and followed for an average
of 11 years. The main findings were that black participants
were less likely than white participants to take low-dose
aspirin for CVD primary prevention, regardless of predicted
risk, age, sex, comorbidities, concomitant use of NSAIDs,
household income, or education; and low-dose aspirin use
was associated with a trend toward decreased risk of
ischemic cardiac death in white participants, especially in
women, but not in black participants.
Overall population estimates of self-reported low-dose
aspirin use for primary CVD prevention obtained from the
2012–2015 National Health Interview Survey ranged from
Figure 2. Impact of race/ethnicity on low-dose aspirin use in
the high-risk category. Forest plot summarizing adjusted odds
ratio (95% CI) of low-dose aspirin use in black and white
participants according to selected variables among the SCCS
(Southern Community Cohort Study) participants belonging to the
Framingham 10-year high-risk category (≥10%) at enrollment.
Results are derived from stratified multivariate logistic regression
models. Models were adjusted for the following variables: year of
SCCS enrollment, age at enrollment, sex, diabetes mellitus status,
medical history of ulcer, concomitant use of NSAIDs, annual
household income, and education.
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Table 4. Multivariate Analysis of Factors Associated With Low-Dose Aspirin Use for Primary Prevention of CVD in the SCCS Based
on Estimations of Multiple Imputed Data
Variable
Model 1 Model 2 Model 3
OR (95% CI) P Value* OR (95% CI) P Value* OR (95% CI) P Value*
Race/ethnicity
White Ref. Ref. Ref.
Black 0.61 (0.59–0.64) <0.001 0.72 (0.69–0.75) <0.001 0.78 (0.74–0.82) <0.001
Year of SCCS enrollment
2002–2003 . . . . . . Ref. Ref.
2004–2005 . . . . . . 1.56 (1.47–1.65) <0.001 1.41 (1.33–1.50) <0.001
2006–2007 . . . . . . 1.86 (1.74–1.98) <0.001 1.77 (1.66–1.89) <0.001
2008–2009 . . . . . . 1.64 (1.53–1.77) <0.001 1.61 (1.49–1.73) <0.001
Age, y
40–49 . . . . . . Ref. Ref.
50–59 . . . . . . 1.87 (1.77–1.97) <0.001 1.83 (1.73–1.93) <0.001
60–69 . . . . . . 2.96 (2.78–3.16) <0.001 2.98 (2.79–3.19) <0.001
70–79 . . . . . . 3.70 (3.36–4.07) <0.001 4.11 (3.73–4.53) <0.001
Sex
Female . . . . . . Ref. Ref.
Male . . . . . . 0.67 (0.64–0.70) <0.001 0.76 (0.72–0.79) <0.001
10-y CVD risk
Low risk . . . . . . Ref. Ref.
Intermediate risk . . . . . . 1.32 (1.18–1.49) <0.001 1.29 (1.15–1.45) <0.001
High risk . . . . . . 2.08 (1.88–2.29) <0.001 1.64 (1.48–1.82) <0.001
Diabetes mellitus
No . . . . . . . . . . . . Ref.
Yes . . . . . . . . . . . . 2.49 (2.37–2.62) <0.001
History of ulcer
No . . . . . . . . . . . . Ref.
Yes . . . . . . . . . . . . 1.07 (1.00–1.14) 0.050
Concomitant NSAIDs
No . . . . . . . . . . . . Ref.
Yes . . . . . . . . . . . . 1.53 (1.46–1.61) <0.001
Annual household income
<$15 000 . . . . . . . . . . . . Ref.
$15 000 to <$25 000 . . . . . . . . . . . . 1.18 (1.11–1.24) <0.001
$25 000 to <$50 000 . . . . . . . . . . . . 1.41 (1.32–1.50) <0.001
≥$50 000 . . . . . . . . . . . . 1.82 (1.69–1.97) <0.001
Education
Less than high school . . . . . . . . . . . . Ref.
High school completed . . . . . . . . . . . . 1.13 (1.07–1.20) <0.001
Higher than high school . . . . . . . . . . . . 1.25 (1.18–1.33) <0.001
Model 1: includes race/ethnicity. Model 2: Model 1+year of SCCS enrollment, age at enrollment, sex, and Framingham 10-year CVD risk category. Model 3: Model 2+diabetes mellitus
status, history of ulcer, concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs), annual household income, and education level. CVD indicates cardiovascular disease; OR, odds
ratio; Ref., referent; SCCS, Southern Community Cohort Study.
*P value from Wald test compared with ref.
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18% for low-risk individuals to 31% for high-risk individ-
uals.18 Similar estimates were obtained from the National
Health and Nutrition Examination Survey 2011–2012.19 The
self-reported rates of low-dose aspirin use in the SCCS are
lower, particularly among black participants (with aspirin use
reported by 27% of white and 18% of black participants at high
CVD risk; Table 2). This finding may be partially explained by
different population characteristics among studies and
changes in low-dose aspirin recommendations over time.
Importantly, our study demonstrates that low-dose aspirin use
by black patients is consistently lower compared with white
participants across all risk categories examined, even after
adjusting for socioeconomic status and other relevant
covariates—a detail that could not be investigated in previous
smaller studies.5–8,20 The reason for these racial and ethnic
disparities is unclear but is likely multifactorial in origin.6
Cultural barriers, mistrust of the healthcare establishment,
and disparities throughout the continuum of prevention and
care, including access to and quality of health care, are
plausible factors.21–23
The large sample of participants allowed us to provide
insights into other factors independently associated with low-
dose aspirin use. In the SCCS, the adjusted odds of low-dose
aspirin use were 25% lower in male compared with female
participants. The Minnesota Heart Survey enrolled a predom-
inantly metropolitan white middle- to high-income population
showing consistently lower rates of low-dose aspirin use for
CVD primary prevention in women than in men over time24;
however, a recent nationwide survey of US adults did not find
differences in use by sex.25 Study setting and population
differences, as well as variations in aspirin use ascertainment
and statistical modeling, might at least partially explain these
conflicting results. We observed that history of peptic ulcer
was not associated with reported low-dose aspirin use,
whereas concomitant use of NSAIDs was associated with an
increase in use. The latter may be evidence of increasing
problems of polypharmacy, especially in elderly patients.26
Interestingly, our data suggest that the use of low-dose aspirin
for the primary prevention of CVD significantly increased from
2002 to 2007 and then stabilized thereafter. A similar
temporal evolution was observed across all CVD risk
categories and perhaps may be explained by the publication
of the USPSTF and American Heart Association (AHA)
guidelines on primary prevention in 2002, which encouraged
Table 5. Incident Cases and Incidence Rates of Ischemic Cardiac Death Among SCCS Participants Stratified by Age, Race/
Ethnicity, and Sex
White White Women White Men Black Black Women Black Men
All ages, n 19 459 12 462 6997 45 772 26 736 19 036
Incident cases, n 395 196 199 830 363 467
Person-years 197 122 128 583 68 538 499 891 298 058 201 834
Incidence rate 2.00 (1.82–2.21) 1.52 (1.33–1.75) 2.90 (2.53–3.34) 1.66 (1.55–1.78) 1.22 (1.10–1.35) 2.31 (2.11–2.53)
40–49 y, n 7923 4917 3006 23 358 13 168 10 190
Incident cases, n 125 56 69 271 101 170
Person-years 81 886 51 909 29 976 263 697 150 200 113 497
Incidence rate 1.53 (1.28–1.82) 1.08 (0.83–1.40) 2.30 (1.82–2.91) 1.03 (0.91–1.16) 0.67 (0.55–0.82) 1.50 (1.29–1.74)
50–59 y, n 6894 4491 2403 15 362 8923 6439
Incident cases, n 152 71 81 303 125 178
Person-years 69 804 46 481 23 323 163 993 98 605 65 388
Incidence rate 2.18 (1.86–2.55) 1.53 (1.21–1.93) 3.47 (2.79–4.32) 1.85 (1.65–2.07) 1.27 (1.06–1.51) 2.72 (2.35–3.15)
60–69 y, n 3646 2396 1250 5444 3518 1926
Incident cases, n 65 41 24 174 85 89
Person-years 36 213 23 999 12 214 56 787 38 061 18 726
Incidence rate 1.79 (1.41–2.29) 1.71 (1.26–2.32) 1.96 (1.32–2.93) 3.06 (2.64–3.55) 2.23 (1.81–2.76) 4.75 (3.86–5.85)
70–79 y, n 996 658 338 1608 1127 481
Incident cases, n 53 28 25 82 52 30
Person-years 9219 6194 3025 15 415 11 192 4223
Incidence rate 5.75 (4.39–7.52) 4.52 (3.12–6.55) 8.26 (5.58–12.23) 5.32 (4.28–6.61) 4.65 (3.54–6.10) 7.10 (4.97–10.16)
Incidence rate is per 1000 person-years (95% CI). SCCS indicates Southern Community Cohort Study.
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the prescription of low-dose aspirin for intermediate- and
high-risk patients.27,28
We observed overall higher incidence of ischemic cardiac
death in white than black participants, particularly in those
aged 40 to 59 years. Available statistics from the United
States overall suggest that non-Hispanic black people have
higher ischemic heart disease mortality rates than white
people, ranging from 1.3 to 2.8 cases per 1000 person-years
in people aged 45 to 64 years, which might be partially
explained by socioeconomic inequalities.29–31 Within the
SCCS, however, socioeconomic status tends to be low among
both black and white participants, and we observed lower all-
cause mortality among black versus white participants.10 The
reasons for such a lower risk of mortality among black
participants in the SCCS are unclear. The influence of
confounding from unmeasured resiliency factors in US black
communities cannot be excluded. The volunteer participation
in the study may be another possibility, including a stronger
“healthy volunteer” effect in black than white participants.10
The substantial socioeconomic status overlap between black
and white participants in the SCCS and the fact that the SCCS
enrolled low-income rural as well as urban populations that
are frequently underrepresented in other cohorts could be
another factor responsible of the different racial/ethnic
outcome rates observed in other studies.11 Nevertheless,
similar lower rates of ischemic heart disease mortality in
black participants (compared with white participants) have
been also reported in US urban-centered studies.32 Further
research is required to determine the possibility of a racial/
ethnic disparity paradox according to particular geographical
or socioeconomic characteristics, which would be equally
concerning.
Importantly, the potential of differential treatment effects
of low-dose aspirin use by race/ethnicity for primary preven-
tion of CVD has not been well studied. Our data suggest that
low-dose aspirin use is associated with a decreased risk of
ischemic cardiac death in white patients, especially in women,
but not in black patients. These racial/ethnic and sex
differences were consistent when the analysis was restricted
to the group with high CVD risk and in high-risk individuals
aged 50 to 69 or 50 to 59 years, for whom the use of low-
dose aspirin may be recommended for the primary prevention
of CVD according to USPSTF 2016 guidelines.1 The reasons
for this racial/ethnic differential effect are speculative but
could include higher rates of inadequate medication adher-
ence,33,34 reduced response to antiplatelet therapy,35 unrec-
ognized risks of concomitant use of over-the-counter drugs
diminishing the potential beneficial effect of low-dose aspirin
(eg, NSAIDs),36–38 and poor control of other risk factors.31,34
It is unlikely that socioeconomic status plays a major role in
this differential effect by race/ethnicity because the partic-
ipants included in this cohort had minor differences in income
levels, which were included in the models for adjustment.
Nevertheless, the role of low-dose aspirin in the general
population without CVD remains controversial. The USPSTF
2016 guidelines narrowed the recommendations to high-risk
Table 6. Adjusted Relative Risk of Incident Ischemic Cardiac Death According to Low-Dose Aspirin Use Among SCCS Participants
Stratified by Age, Race/Ethnicity, and Sex
White White Women White Men Black Black Women Black Men
All risk, all ages
Participants, n 19 459 12 462 6997 45 772 26 736 19 036
HR (95% CI) 0.86 (0.68–1.10) 0.72 (0.51–1.02) 1.03 (0.73–1.45) 1.18 (0.98–1.40) 1.05 (0.82–1.35) 1.32 (1.03–1.70)
High CVD risk, all ages
Participants, n 12 769 6496 6273 31 822 14 723 17 099
HR (95% CI) 0.82 (0.63–1.06) 0.71 (0.49–1.03) 0.94 (0.66–1.34) 1.17 (0.97–1.40) 1.02 (0.78–1.33) 1.33 (1.04–1.71)
High CVD risk, 50–69 y
Participants, n 8253 4694 3559 18 031 9889 8142
HR (95% CI) 0.78 (0.57–1.08) 0.71 (0.45–1.12) 0.89 (0.56–1.41) 1.10 (0.88–1.39) 0.93 (0.67–1.30) 1.30 (0.95–1.77)
High CVD risk, 50–59 y
Participants, n 5022 2713 2309 12 786 6570 6216
HR (95% CI) 0.74 (0.49–1.12) 0.63 (0.34–1.17) 0.86 (0.50–1.50) 1.04 (0.77–1.41) 0.93 (0.60–1.45) 1.15 (0.76–1.74)
Relative risk estimated by HR (95% CI) for fatal ischemic cardiac event among those who used and did not use low-dose aspirin (reference), obtained from stratified Cox proportional
hazards models. All models were adjusted by Framingham 10-year CVD risk category, age at enrollment, sex, race/ethnicity, diabetes mellitus status, and household income, otherwise
were not considered as stratification variables. Results are presented for the overall study population (all risks, all ages) and in high-risk (≥10% CVD risk) participants by race/ethnicity for
any age and according to the US Preventive Services Task Force 2016 recommendations on low-dose aspirin use for primary prevention of CVD (50–69 and 50–59 years of age). CVD
indicates cardiovascular disease; HR, hazard ratio; SCCS, Southern Community Cohort Study.
DOI: 10.1161/JAHA.119.013404 Journal of the American Heart Association 11


















 http://ahajournals.org by on O
ctober 20, 2020
individuals aged 50 to 69 years, removed the previous
distinction by sex, and downgraded the recommendation
from grade A to grade B for the group aged 50 to 59 years and
to grade C for the group aged 60 to 69 years. Along the same
lines, an overview of systematic reviews concluded that high-
quality evidence supports aspirin for primary CVD preven-
tion.3 In contrast, and as supported by several meta-analyses
and clinical trials suggesting no benefit of low-dose aspirin
and/or a potential increase in severe bleeding risk,39–43 the
“2016 European Guidelines on Cardiovascular Disease
Prevention in Clinical Practice” stated that antiplatelet therapy
is not recommended in individuals without CVD.44 Based on
recent trials showing no net benefit,45–47 the 2019 American
College of Cardiology and AHA “Guideline on the Primary
Prevention of Cardiovascular Disease” recommends that low-
dose aspirin should be used infrequently in the routine
primary prevention of CVD.48 Our study suggests that the
effect of low-dose aspirin for the primary prevention of CVD
may differ by race/ethnicity, raising the possibility of no
benefit among black patients. There are no plausible reasons
to think that low-dose aspirin might be harmful to black
patients. Therefore, the trend toward increased risk of
ischemic cardiac death shown in particular subgroups of
black low-dose aspirin users in this observational study might
be due to residual confounding (ie, black participants on low-
dose aspirin might have been identified as having higher CVD
risk in a manner somehow not fully accounted for in the
models).
Our study has several limitations worth noting. Perhaps
the greatest is the possibility of confounding by indications
that were not completely captured in the covariate adjust-
ments (ie, residual confounding). Another limitation is that
Figure 3. Follow-up of ischemic cardiac death according to low-dose aspirin use in high-risk participants. Race/ethnicity-stratified Kaplan–
Meier curves illustrating cumulative incidence of ischemic cardiac death during follow-up according to low-dose aspirin use. Results are
presented for participants in the Framingham 10-year high-risk category (≥10%) aged 50 to 69 years or 50 to 59 years, for whom the use of low-
dose aspirin may be considered for the primary prevention of CVD according to the US Preventive Services Task Force 2016 recommendations.
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we were unable to assess the exact duration of aspirin
therapy. For many participants, we had no information on
whether and when the individual initiated or stopped low-
dose aspirin use after baseline questionnaire response; this
could result in possible misclassification effects of unknown
magnitude and direction. Nevertheless, baseline low-dose
aspirin use did not demonstrate a time-varying effect on
mortality in our analysis, meaning that hazard ratios
associated with low-dose aspirin use were constant over
time. To account for temporal trends of low-dose aspirin use,
we performed a sensitivity survival analysis including the
year at participant enrollment as a covariate, and differences
between models were minimal (results not shown). The fact
that the study significantly relied on self-reported data might
make the analysis susceptible to recall and misclassification
bias; however, these methods are common to many
epidemiological studies. Furthermore, a series of indepen-
dent validation studies demonstrated the reliability of the
questionnaire within the SCCS population for many of the
collected variables.9 Actual lipid profile was not available,
and thus the 10-year CVD risk based on the pooled cohort
equations could not be calculated.13 Nevertheless, the
Framingham risk equation has been validated in multiple
ethnicities.49 In fact, the Framingham original and offspring
cohorts were used, among others, to derive the pooled
cohort equations.13 Similarly, a significant proportion of
participants in this study did not undergo blood pressure
measurements. By imputing normal blood pressure values
according to self-reported hypertension status when they
were missing, our calculations may underestimate actual
cardiovascular risk.14 Nevertheless, the prevalence of hyper-
tension diagnosis and other clinical and sociodemographic
characteristics was similar among individuals with and
without actual blood pressure values available (Table 8).
Furthermore, the study conclusions were similar when
missingness of blood pressure was addressed by several
means, including multiple imputation procedures and the
replication of the results in the full cohort of participants by
considering their predicted CVD risk category based on the
number of cardiovascular risk factors (data not shown), as
done previously by others.7,50–52 The major strengths of our
study include the large sample size and the comparison of
black and white populations of similar socioeconomic status,
allowing examination of low-dose aspirin use patterns and
CVD incidence effects of aspirin by race/ethnicity less
confounded by socioeconomic status. The SCCS cohort
includes a substantial number of participants from disad-
vantaged and low-income populations that have been
underrepresented, so our study provides relevant insights
not available in most previous studies.
In conclusion, in this predominantly high-risk and low-
income biracial/ethnic large cohort, we found that black
participants were less likely to take aspirin for primary
prevention of CVD and that low-dose aspirin use was
Table 7. Adjusted Relative Risk of Incident Ischemic Cardiac Death According to Low-Dose Aspirin Use Among SCCS Participants
Stratified by Age, Race/Ethnicity, and Sex Based on Estimations of Multiple Imputed Data
White White Women White Men Black Black Women Black Men
All risk, all ages
Participants, n 19 459 12 462 6997 45 772 26 736 19 036
HR (95% CI) 0.87 (0.68–1.11) 0.73 (0.51–1.04) 1.03 (0.73–1.45) 1.18 (0.99–1.41) 1.05 (0.82–1.35) 1.32 (1.03–1.70)
High CVD risk, all ages
Participants, n 12 769 6496 6273 31 822 14 723 17 099
HR (95% CI) 0.82 (0.63–1.08) 0.72 (0.48–1.07) 0.94 (0.65–1.35) 1.13 (0.94–1.37) 0.97 (0.74–1.28) 1.31 (1.02–1.69)
High CVD risk, 50–69 y
Participants, n 8253 4694 3559 18 031 9889 8142
HR (95% CI) 0.78 (0.56–1.10) 0.72 (0.44–1.16) 0.88 (0.55–1.40) 1.11 (0.88–1.40) 0.94 (0.67–1.33) 1.28 (0.93–1.76)
High CVD risk, 50–59 y
Participants, n 5022 2713 2309 12 786 6570 6216
HR (95% CI) 0.74 (0.48–1.14) 0.64 (0.33–1.25) 0.85 (0.48–1.49) 1.03 (0.75–1.41) 0.93 (0.59–1.49) 1.12 (0.74–1.72)
Relative risk estimated by HR (95% CI) for fatal ischemic cardiac event among those who used and did not use low-dose aspirin (reference), obtained from stratified Cox proportional hazard
models run on multiple imputed data. All models were adjusted by Framingham 10-year CVD risk category, age at enrollment, sex, race/ethnicity, diabetes mellitus status, and household
income, otherwise were not considered as stratification variables. Results are presented for the overall study population (all risk, all ages) and in high-risk (≥10% CVD risk) participants by
race/ethnicity both any age or according to the US Preventive Services Task Force 2016 recommendations on low dose aspirin use for primary prevention of CVD (50–69 and 50–59 years
of age). Because estimation samples varied across imputations in high-risk subgroups, n reflects the number of individuals as in Table 6. CVD indicates cardiovascular disease; HR, hazard
ratio; SCCS, Southern Community Cohort Study.
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associated with decreased incidence of ischemic cardiac
death in white participants, especially in women, but not in
black participants. Confounding by indication in these
observational data cannot be ruled out, and the findings
warrant confirmation in further studies before any clinical
recommendation is given.
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